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Abstract: Pelargonium species contribute significantly to the health care of a large 
population in the Southern African region, as part of a long-standing medical system 
intimately linked to traditional healing practices. Most notably, extracts of the roots of  
P. sidoides have commonly been applied for the treatment of dysentery and diarrhoea but 
only occasionally for respiratory complaints. Clinical trials have shown that a modern 
aqueous-ethanolic formulation of P. sidoides extracts (EPs® 7630) is an efficacious 
treatment for disorders of the respiratory tract, for example bronchitis and sinusitis. It 
should be noted that EPs® 7630 is the most widely investigated extract and therefore is the 
focus of this review. In order to provide a rationale for its therapeutic activity extracts have 
been evaluated for antibacterial activity and for their effects on non-specific immune 
functions. Only moderate direct antibacterial capabilities against a spectrum of bacteria, 
including Mycobacteria strains, have been noted. In contrast, a large body of in vitro 
studies has provided convincing evidence for an anti-infective principle associated with 
activation of the non-specific immune system. Interestingly, significant inhibition of 
interaction between bacteria and host cells, a key to the pathogenesis of respiratory tract 
infections, has emerged from recent studies. In addition, antiviral effects have been 
demonstrated, including inhibition of the replication of respiratory viruses and the enzymes 
haemagglutinin and neuraminidase. Besides, an increase of cilliary beat frequency of 
respiratory cells may contribute to the beneficial effects of P. sidoides extracts. This 
example provides a compelling argument for continuing the exploration of Nature and 
traditional medical systems as a source of therapeutically useful herbal medicines. 
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1. Introduction 
Infectious diseases have been and continue to be an ever-present threat to mankind. Despite medical 
advances, infectious diseases are still a cause of death for millions around the World. Of the estimated 
57 million deaths that occur throughout the World each year, more than 25 percent are directly caused 
by infectious diseases [1]. More than 90 percent of the worldwide mortality from infectious diseases is 
caused by only a handful of diseases, including lower respiratory infections, HIV/AIDS, diarrheal 
diseases, tuberculosis, malaria and measles (Figure 1) [1]. New targets for novel anti-infective drugs 
need to be identified, particularly in the light of the emergence of drug resistant strains. 
Figure 1. Global deaths and infectious diseases. 
 
Many herbal medicines have ethnomedicinal uses for the treatment of infectious conditions such as 
respiratory ailments. However, research programmes are important for validating the traditional use, 
providing evidence for the safety and the quality of the plant material. That traditionally used herbal 
medicines may well provide the basis for the development of a modern and highly successful 
phytopharmaceutical that meets the internationally required criteria of quality, safety and efficacy for 
an evidence-based therapy is exemplarily shown for Pelargonium sidoides. Members of the genus 
Pelargonium are highly valued by traditional healers and the South African native population for their 
curative and palliative effects in the treatment of gastrointestinal disorders, while interest in  
P. sidoides has been heightened by reports of therapeutic benefits in infectious conditions of the 
respiratory tract such as tuberculosis and related diseases. The interesting ethnobotanical and 
commercial history, as well as the phytochemical profile of this medicinal plant, have been reviewed in 
detail elsewhere and are thus not reiterated (vide infra). This report is aimed at reviewing the current 
knowledge on the mechanisms of the underlying beneficial effects of P. sidoides and the related herbal 
drug preparation EPs® 7630. Notably, this special extract has been the subject of 20 clinical studies 
involving more than 9,000 patients, including 3,900 children as young as 1 year, reviewed repeatedly 
elsewhere (vide infra). The objective of this review is to show the potential of a traditional plant,  




P. sidoides, for the defence against pathogens and the improvement of immune functions at various 
levels and, thus, the invaluable role that natural products continue to play in the drug discovery process 
in the areas of infectious and other diseases. 
2. Discussion 
2.1. Traditional and Therapeutic Uses of Pelargonium Sidoides 
Historically, the ethnomedicinal use of P. sidoides in the traditional medical systems of southern 
Africa is mainly associated with gastrointestinal disorders (diarrhoea and dysentery), whereas only 
some records exist for the treatment of respiratory conditions (tuberculosis, coughs, colds, sore throat) 
and sources of this information are not always provided [2-5]. In this context it appears important to 
note the general problems surrounding the taxonomic classification of Pelargonium species, as 
reflected in the past by numerous revisions. In southern Africa, tuberculosis is one of the most 
commonly notified diseases. In the absence of an effective chemotherapy in earlier days, traditional 
healers were widely consulted and many local plants were used to alleviate tuberculosis-related 
symptoms. As for P. sidoides, a key role in the successful introduction of a profound traditional herbal 
remedy in modern phytotherapy in Europe is linked to Charles Henry Stevens, who believed he was 
cured by taking a brew prepared from the roots and subsequently tried to introduce “Stevens’ 
Consumption Cure” on the market in Great Britain [5-8].  
This herbal treatment is seeing increasing popularity, not only in southern Africa but also in European 
countries, in the Commonwealth of Independent States, the Baltic States and in Mexico [4,9]. Following 
the well-documented therapeutic benefits in infectious conditions of the respiratory tract, a modern 
formulation of the roots of P. sidoides, EPs® 7630 (exclusively contained in Umckaloabo®, marketed 
by Spitzner Arzneimittel, Ettlingen, Germany), has been elaborated from this traditional herbal 
medicine. EPs® 7630 is a special aqueous ethanolic extract. Results from a number of clinical studies 
including several randomised, double-blind and placebo-controlled trials, support the use of 
Umckaloabo® in respiratory tract infections such as bronchitis, sinusitis and tonsillitis. Several  
post-marketing surveillance studies are available, demonstrating the safety and tolerability of the 
traded product [10-18]. Umckaloabo® was approved in Germany as a drug for treating acute bronchitis. 
This illness is one of the most frequent diagnoses in medical practice and predominantly caused by 
RNA viruses. Only in less than 10% of cases non-viral agents play a role in its etiology [19]. 
Surprisingly, prescription of antibiotics for infections of viral origin is still wide-spread even though 
their efficacy is limited to bacterial infections [20]. One purpose might be to avoid a secondary 
bacterial superinfection with group A β-hemolytic streptococci. Development of resistant bacteria is a 
disadvantage of non-indicated antibiotic therapy. Based on clinical studies, the Pelargonium-based 
preparation offers an alternative therapeutic agent to otherwise not indicated antibiotic treatment. 
2.2. Antimycobacterial and Respiratory Tract Related Antibacterial Activity 
Following earlier claims of antimycobacterial efficacy of P. sidoides, methanol extracts of the roots 
and some of its characteristic phenol and coumarin constituents were tested for this particular 
biological activity. Using the radiorespirometric BACTEC method, the extracts showed 




antimycobacterial activity against Mycobacterium tuberculosis (96% at 12.5 µg/mL), while none of the 
purified compounds tested exhibited any antimycobacterial activities under these experimental 
conditions. The same extract exhibited weak activities against M. tuberculosis (MIC of 100 µg/mL) as 
assessed in a broth microdilution alamar blue assay. Rifampicin, used as reference, showed an MIC of 
0.06 µg/mL under the experimental conditions used. Independent support of the weak 
antimycobacterial activity of P. sidoides was provided by similar studies of acetone and ethanol root 
extracts using M. tuberculosis and M. smegmatis as test organisms, while coumarins and flavonoids 
isolated from this plant source again proved inactive [4]. With MICs of >1,024 µg/mL, an aqueous 
acetone extract of P. sidoides showed negligible antimycobacterial activities against the rapidly 
growing avirulent M. smegmatis in a broth microdilution assay [21]. Similar results were obtained 
from testing the extracts against M. aurum, a species reported to be predictive of activity against  
M. tuberculosis because of their comparable drug sensitivity profiles. This finding suggests that direct 
antimycobacterial activity apparently depends not only on the strain of mycobacterium, but also 
strongly on extract preparation and composition.  
In the course of a search for antimycobacterial constituents some straight-chain fatty acids present  
in n-hexane root extracts with activity against a panel of rapidly growing mycobacteria were  
identified [22,23]. Interestingly, all the saturated fatty acids except lauric acid were devoid of any 
antimycobacterial activity, whereas unsaturated analogues, including oleic acid and linoleic acid, were 
active, with the latter being the most potent one (MIC of 2 µg/mL against M. aurum). However, these 
data do not provide convincing evidence for an antimycobacterial principle of P. sidoides. In 
traditional medicine decoctions and infusions are used, thus putting into question the presence of 
effective levels of lipophilic constituents in aqueous preparations. Furthermore, it should be noted that 
Mycobacteria are intracellularly residing pathogens, while the in vitro protocols conducted reflect a 
direct action on these pathogens. That P. sidoides root extracts apparently show limited 
antimycobacterial activity under these test conditions is reflected in further studies [24,25]. Taking into 
account the overall moderate antimycobacterial activity in experiments carried out so far, it is highly 
likely that the claimed effective use of P. sidoides in the treatment of tuberculosis may be due to 
stimulation of the non-specific immune system rather than any direct action on Mycobacteria 
pathogens. The antimycobacterial principle of this popular Pelargonium species remains to  
be identified. 
Parallel work focused on the evaluation of the antibacterial activity of P. sidoides against a panel of 
microorganisms (Staphylococcus aureus, Streptococcus pneumoniae, ß-hemolytic Streptococcus, 
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus 
influenzae) associated with respiratory diseases [26]. However, the in vitro antibacterial effects of an 
aqueous acetone extract, fractions obtained thereof from successive partitions between water and 
organic solvents (ethyl acetate, n-butanol, MICs of 600–7,500 µg/mL), and a range of isolated 
compounds (MICs of 200–1,000 µg/mL) have been shown to be only modest compared with classic 
antibiotics. It should be noted that the standardized root extract EPs® 7630 has hitherto not been 
subjected to similar antibacterial studies, though moderate activities are commonly noted. Independent 
support of weak direct antibacterial activities followed from studies using the liquid preparation 
Umca® and isolates (Streptococcus pneumonia, S. pyogenes, S. viridans, Staphylococcus aureus,  
S. epidermis, Neisseria spp., Moraxella catarrhalis, Haemophilus influenza) obtained from the throat 




cultures of patients [27]. Employing a microdilution broth method, MIC values were in the range of 
200–1,600 µg/mL, with MICs >800 µg/mL for most of the bacteria tested.  
These disappointing findings prompted a series of studies attempting to demonstrate indirect 
antibacterial mechanisms that could provide a clue to the anti-infective properties of P. sidoides-based 
herbal medicines [28]. Adhesion of pathogenic bacteria to the host cell surface is a crucial event in 
colonization and infection. Inhibition of the microbial docking process to epithelial cells at an early 
stage would be effective in protecting host cells from infection. Using fluorescent-labelled group  
A-streptococci and viable human laryngeal cells (HEp-2) as a model, flow cytometric measurements 
showed prominent (by up to ca. 45% compared with untreated cells) anti-adhesive and anti-invasive 
capabilities of EPs® 7630 in a concentration dependent manner (< 30 µg/mL). Notably, inhibition of 
streptococcal adhesion to host cells was only evident when the bacteria were pre-treated with  
EPs® 7630, indicating that the interaction of the anti-adhesive principle occurred only with the bacterial 
outer membane surface and not with binding sides at the epithelial surface.  
Recent experiments revealed that proanthocyanidins (Figure 2) play a decisive role in the observed 
inhibition of group A-streptococci docking process to HEp-2 cells, as concluded from the apparent 
‘missing’ activity of phenolic-free extracts [29]. The picture that emerged from these anti-adhesive 
studies including homogeneous epicatechin- and catechin-based polyflavans, a ‘mixed’ procyanidin 
sample, a prodelphinidin test substance as well as an A-type proanthocyanidin provided evidence that 
the anti-streptococcal activity of EPs® 7630 polyphenols appeared to be due to the prodelphinidin-type 
substructure (epigallocatechin and gallocatechin extender units). Pre-treatment experiments indicated 
that the interaction of the anti-adhesive proanthocyanidins occurred only with binding factors on the 
bacterial surface. The blocked molecules, for example fibronectin- and collagen-binding adhesions [30], 
remain to be identified. 
Figure 2. Representative structure of the proanthocyanidins of Pelargonium sidoides with 
epigallocatechin and gallocatechin extender units as well as doubly linked A-type elements. 
 
Interestingly, bacterial attachment was enhanced ca. 7-fold under the influence of EPs® when using 
buccal epithelial cells that, noticeably, are mostly dead [28]. Inactivation of the trapped microorganisms 
may be explained by the fact that the decaying buccal cells are physiologically sloughed off and 
swallowed with the saliva. In this way the intercepted pathogens are not available for adhesion to intact 
A-type element 






































cells. Taking into account the fairly high inhibition of bacterial adhesion to viable epithelial cells, these 
indirect antibacterial activities have beneficial effects on infectious conditions. The impact of  
EPs® 7630 on microbial adhesion was also demonstrated in studies with Helicobacter pylori [31,32]. 
Again, pre-treatment of fluorescent-labelled H. pylori with the P. sidoides extract inhibited the 
adherence to human gastric mucosa cells in a dose-dependent manner. However, the underlying 
biologically active principle remains to be identified. Taken together, the demonstrated anti-adhesive 
mechanism may well contribute to the anti-infective activity of EPs® 7630 at an early time point of a 
bacterial infection.  
Also worthy of mention is the potential of the P. sidoides extract to significantly inhibit streptococcal 
invasion into HEp-2 cells. Similarly to the anti-adhesion activity, polyphenols may interfere with 
extracellular proteins produced by the bacteria to facilitate invasiveness. Clearly, further studies are 
needed to get insight into the underlying principle that bacteria employ to invade our cells. From a 
more medicinal viewpoint, inhibition of the bacterial invasion of epithelial cells protects the host from 
pathogens that evade host defences and antibiotic therapy. Once inside the host cells, recurrent 
streptococcal infections may well occur. The demonstrated inhibition of the streptococcal invasion thus 
prevents recurrent infections. 
Although the above findings have provided evidence for both direct and indirect antibacterial 
properties of P. sidoides, the pronounced anti-infective capabilities of this herbal medicine cannot 
adequately be explained merely on the basis of the observed antibacterial activities. 
2.3. Effect on the Mucociliary System of Respiratory Cells 
The mucociliary system represents a defence mechanism of the nasal cavity and the bronchial tree for 
cleaning the air of bacteria and foreign particles, with the ciliary beat frequency (CBF) being an 
important parameter for determining its efficacy. EPs® 7630 significantly and concentration-dependently 
increased CBF of an adherent monolayer culture of human nasal epithelium cells. At 30 µg/mL, the 
increase was ca. 125% compared to the equilibrium phase [33]. After washing procedures the CBF 
returned to that of the equilibration period. However, subsequent examinations have to prove the effect 
under in vivo conditions with emphasis on the mucociliary clearance.  
2.4. Antiviral Effects 
Since respiratory tract infections are frequently caused by viruses (> 90% of cases) [19], it is 
noteworthy that EPs® 7630 exhibited antiviral effects in a number of assays. For example, prominent 
cytoprotective effects were observed in a fibroblast-virus protection assay [34]. In this test model, 
supernatants of activated macrophages were transferred to a monolayer of encephalomyocarditis virus 
(EMCV)- and IFN-sensitive murine L 929 fibroblasts (ML929F) before exposure to EMCV 
suspensions. IFN activity was assessed by observing the protection of ML929F against the cytopathic 
effect (CPE) induced by infection with EMCV. The relative number of viable cells was determined 
spectrophotometrically using crystal violet as staining reagent for protected cells [35]. Antiviral 
protection was expressed in U/mL, defined as the reciprocal value of the supernatant dilution that 
would inhibit 50% of the CPE induced by EMCV in ML929F. These values were correlated with the 
IFN standard (100 U/mL) to account for any fluctuation in assay sensitivity. Prominent cytoprotective 




effects (ca. 60%) were observed for EPs® 7630 at remarkably low doses (0.8 µg/mL), with complete 
inhibition of CPE at 1.4 µg/mL sample concentration [34]. Recent refined work showed that the 
supernatant of bone marrow-derived macrophages (BMMΦ) stimulated with 10 µg/mL of EPs® 7630 
produced an antiviral activity of ca. 80 U/mL, which was similar to that of the LPS (1 ng/mL)  
response [36]. Known antiviral factors are members of the IFN family classified in type I and type II 
interferons according to receptor specificity and sequence homology [37,38]. Since the functional 
assay does not discriminate between IFN-α, IFN-β and IFN-γ, the authors’ interest focused on their 
detection using ELISA. All attempts to identify any potential antiviral compound were unsuccessful, 
suggesting that either the production of effective IFN levels was below the detection limits of the 
assays, synergistic effects may contribute to the powerful overall action or other elements of the 
immune system such as type III IFN [39] are the responsible effective agents. That eicosanoids may 
play a role in the control of viral infection may be excluded. EPs® 7630 was shown to suppress their 
production in calcium-ionophore stimulated human granulocytes [40]. Previous studies with a range of 
proanthocyanidins indicated that members of this class of compounds possess pronounced IFN-like 
activities [41]. Their presence in the extract may also be an inducing factor. Worthy of mention is that 
the extract did not induce any cytoprotective effects when directly exposed to ML929F, clearly 
indicating an indirect mode of action.  
As noted, known antiviral factors are members of the IFN family. The apparent modulatory potency 
of EPs® 7630 on IFN levels, endowed with potent antiviral effects and mediating functional activity of 
natural killer cells [42], was demonstrated by enhanced IFN-ß synthesis in human MG-63 
osteosarcoma cells when superinduced with the viral double-stranded RNA analogue polyinosinic 
acid: polycytidylic acid [35]. The effect was only evident in the presence of the infectious component, 
with the maximum augmentation of 200% after application of 3 µg/mL. This remarkable selectivity is 
significant in that activation of the non-specific immune system comes into force only after invasion 
by pathogens.  
Direct antiviral activity of the P. sidoides aqueous extract was first evaluated in vitro against herpes 
simplex virus type 1 (HSV-1) and type 2 (HSV-2) on RC-37 cells using a plaque reduction assay [43]. 
Both herpes viruses cause common infections with recurrent orofacial (HSV-1) and genital lesions 
(HSV-2). Only pretreatment of viruses with the extract and subsequent infection of RC-37 cells 
revealed pronounced antiviral effects in a concentration-dependent manner, with IC50 values of  
0.6 µg/mL and 0.05 µg/mL for HSV-1 and HSV-2, respectively. Taking into account the excellent 
selectivity index defined as the ratio of IC50 values between the cytotoxicity on RC-37 cells  
(0.04 mg/mL) and the antiherpes activity, the antiviral effect is likely due to interactions between the 
virus and extract components which, however, remain to be identified. Notably, at the maximal 
noncytotoxic sample concentration of 10 µg/mL, plaque formation was reduced by ca. 99.9% for 
HSV-1 and HSV-2. The mode of action was investigated by a set of experiments with incubation 
during the adsorption or replication period of the virus. The results showed that addition of the extract 
exclusively during the adsorption period of HSV significantly reduced infectivity. Again, polyphenols 
may represent the underlying active principle, acting in a selective rather than non-specific manner.  
Following the therapeutic use of EPs® 7630 in modern phytomedicine for the treatment of upper 
respiratory tract infections, the demonstrated antiviral effects of this extract against a panel of viruses 
including seasonal influenza A virus strains (H1N1, H3N2), respiratory syncytial virus, human 




coronavirus, parainfluenza virus and coxsackie virus provided evidence of feasible beneficial effects in 
patients suffering from acute bronchitis and related infectious diseases [44]. With the exception of 
coxsackie, all sensitive viruses are enveloped, suggesting that EPs® 7630 inhibits preferably the 
replication of viruses of this category. This was in line with the potential antiviral effects on enveloped 
herpes viruses [43]. In fact, EPs® 7630 did not show any influence on non-enveloped rhino- and 
adenoviruses-induced cytopathogenic effects. Observed varying susceptibilities to EPs® 7630 of 
influenza A subtypes (H1N1, H3N1, H5N1) can be rationalized by mutant haemagglutinins present on 
the surface of the individual influenza viruses. These structurally modified glycoproteins, responsible 
for the binding of the virus to the host cell, may therefore be differently affected by the extract. 
Experiments evaluating the influence of EPs® 7630 on virus-induced cytopathogenic effects in a range 
of cell lines indicated IC50 values > 100 µg/mL. 
The enzyme neuraminidase (sialidase) with its highly conserved active site plays a key role not only 
in the release of virions from infected host cells, but also in their movement through the upper 
respiratory tract [45]. Among the therapeutic options for the treatment and prevention of influenza 
infections, neuraminidase inhibitors are promising candidates to inhibit the spread of the viral 
infections. In view of the claimed antiviral potential related to common colds, EPs® 7630 was 
originally tested for its in vitro neuraminidase inhibiting activity using a fluorometric-based assay [46]. 
Compared to zanamivir (IC50 of 71 µg/mL), the extract exhibited pronounced inhibitory activity for the 
bacterial neuraminidase from Vibrio cholera, with an IC50 value of 0.9 µg/mL [47]. The evidence, 
however, that EPs® 7630 has similar inhibiting activity for the viral neuraminidase in this in vitro 
model demands further investigation. Even more interesting, treatment of the extract with skin powder 
for the removal of tannins produced an inactive sample. The loss of activity of the polyphenol-free 
extract clearly indicated that proanthocyanidins apparently represent the underlying active principle. 
The specificity of EPs® 7630 polyphenols for this biological activity was demonstrated by testing a 
range of proanthocyanidin samples comprised of different flavanyl constituent units (procyanidins, 
prodelphinidins, A-type proanthocyanidins).The data suggested that the neuraminidase inhibiting 
activity of EPs® 7630 may be related to prodelphinidin extender units in oligoflavanoids.  
Independent support of the antiviral activity of EPs® 7630 originated from a current study using 
influenza A strains H1N1, an oseltamivir-resistant H1N1 subtype and H3N2 [48]. The data suggest 
inhibition of the key proteins, haemagglutinin and neuraminidase, present on the surface of the 
influenza virus. This potency was also evident in in vivo experiments with the H1N1 virus. Considering 
the interaction of EPs® 7630 constituents with the two surface glycoproteins that are important for the 
viral replication lifecycle at the early and final stage of infection, the therapeutic benefit of the extract 
may well be seen in the light of an infect prophylaxis and improvement in the infectious condition. 
2.5. Role of the Non-Specific Immune System 
To understand the many effects of P. sidoides on the non-specific immune system and its potential 
role in host response to pathogens, it seems appropriate to illustrate the key components involved in 
the clearing of microbial agents. Since several immunological factors are associated with anti-infective 
responses, only those parameters are briefly described which primarily imply stimulation of the  
non-specific immune system and are closely related to the hitherto known anti-infective principle 




detected in P. sidoides based medicines. A simplified overview of induced cytotoxic defence 
mechanisms is shown in Figure 3. 
Figure 3. Simplified illustration of cytotoxic defence mechanisms of activated macrophages 
induced by the root extract of P. sidoides. 
 
Macrophages are extremely versatile cells involved in a number of complex processes in immune 
responses. When activated they acquire microbicidal effector functions and secrete cytokines, resulting 
in recruitment of immune cells and subsequent elimination of the pathogen by phagocytosis or release 
of reactive oxygen and nitrogen species. Generation of reactive oxygen species is initiated by NADPH 
oxidase. The primary product is superoxide, which can be converted to H2O2 by superoxide dismutase 
and subsequently to hydroxyl radicals and anions. 
Production of nitric oxide and its many congeners (NO) is another key macrophage antimicrobial 
response. NO are important intra- and intercellular regulatory molecules of multiple biological functions, 
including macrophage-mediated cytotoxicity [49-52]. Endogenously derived NO is generated 
enzymatically from L-arginine by constitutive (c) or inducible (i) nitric oxide synthases (NOS) present 
in different cell types and released constantly at physiological levels under the influence of cNOS [53]. 
All NO synthases convert L-arginine and molecular oxygen to L-citrulline and NO. However, 
expression of iNOS in activated macrophages in response to immunological stimuli induces the release 
of large amounts of NO for long periods. Although NO species function beneficially as antimicrobial 
effector molecules in the immune protection against bacteria, parasites and viruses and regulate cell 
survival, the relatively high and sustained level of inducible NO produced during the immune response 
may be harmful, as dramatically shown in septic shock. Accordingly, regulation of NO production is 
important for human health. In the presence of superoxide anion, a series of NO effector molecules 
might prevail that are also involved in the host defence mechanism. 
Although the production of reactive oxygen and nitrogen species considerably contributes to the 
killing of infectious pathogens, the secretion of cytokines from activated macrophages and related cells 




is also an integral component of an effective immune response to a viral or bacterial infection, with 
regulatory functions on the production of these cytotoxic effector species. They act at all levels of the 
immune response and form a complex network of molecules. Among the macrophage-associated 
cytokines, release of tumour necrosis factor (TNF)-α is an essential early step in a signalling cascade 
leading to production of antimicrobial NO [54,55]. Also, TNF-α synergizes with IFN-γ in the 
induction of iNOS and NO production by macrophages, though IFN-γ alone was shown to be capable 
of independently enhancing iNOS transcription and NO release [56,57]. The role that these cytokines 
play in NO-mediated destruction of microbial pathogens prompted in the beginning exploration of 
Pelargonium-induced immune modulatory effects on macrophage functions using functional assays 
such as a fibroblast-lysis assay for release of TNF and a cytopathic effect inhibition assay for IFN-like 
properties (vide infra). Importantly, control of viruses is achieved through IFN-〈 and IFN-ß which are 
produced by host cells, while IFN-γ mediates macrophage activation. 
2.6. Immunomodulatory Activities 
The destabilized defence mechanisms resulting from a viral infection can clear the way for a 
secondary bacterial infection. Recalling the ethnomedicinal use of the roots of P. sidoides in the 
treatment of tuberculosis, it is appropriate to stress that pathogenic mycobacteria have developed 
multiple mechanisms for entering macrophages by a receptor-mediated pathway that is not coupled to 
the activation of macrophage cytotoxic defence mechanisms to ensure their own survival [58]. The fact 
that mycobacteria reside within cells and the less effective direct antibacterial potencies (vide supra) 
suggested that stimulation of the non-specific immune system may contribute to the anti-infective 
activity of P. sidoides extracts. The immediate question thus concerned the factors that contribute  
to the immune control of microbial pathogens and possibly viruses associated with respiratory  
tract infections. 
2.6.1. Phagocytic Activity and Oxidative Burst 
Phagocytosis and related activity of phagocytes play a crucial role in the innate immunity of host 
defence against invading pathogens including bacteria and viruses. Circulating blood phagocytes are 
rapidly recruited to sites of infection. Activated by attached pathogen-associated molecular patterns, the 
microorganisms are ingested by the phagocytes (phagocytosis) followed by the production and release of 
reactive oxygen species (oxidative burst) that contribute to the destruction of pathogens (intracellular 
killing). Using a whole blood-based, flow cytometric assay with Candida albicans as the target 
organism, EPs® 7630 significantly increased the number of phagocytosing cells (maximal enhanced by 
56% after 2 min upon addition of 30 µg/mL of the extract sample) in a concentration-dependent manner. 
With a target to effector cell ratio of 1:1, all yeast cells were ingested after 30 min [59].  
As for the oxidative burst, the application of 30 µg/mL extract similarly led to a marked increase of 
burst-active blood phagocytes for all time points observed beyond 2 min, with a maximum augmentation 
of 120% at 4 min when compared with controls. The stimulation of the burst activity was still 
detectable even when all Candida organisms have already been ingested. Although phagocytic activity 
may strongly depend on the kind of microorganism, this finding clearly demonstrated that the Pelargonium 
extract effectively improved phagocytic activity. Furthermore, results from a microbiological intracellular 




killing assay indicated that the number of surviving yeast cells were reduced by ca. 30% at 120 min 
compared with controls. The benefit of the oral application may be seen in local effects on both the 
resident and invading phagocytes at the site of infection. 
2.6.2. Intracellular Killing of Pathogens and Release of Nitric Oxides 
Experimental infection of macrophages constitutes a particularly versatile model for assessing the 
immunoregulation that occurs during a cell-mediated response to an intracellular pathogen, consistent 
with the previous antitubercular usage of P. sidoides in traditional medicine. For safety reasons and 
convenience, an established in vitro model for infectious diseases was selected in which murine 
macrophages were infected with obligate intracellular Leishmania parasites rather than pathogenic 
Mycobacteria strains [60]. A colorimetric assay was used for assessing the activation of macrophages 
against the intracellular parasites, based on infection of macrophages in suspension culture, exposure 
to the Pelargonium extract, and lysis of the host cells with sodium dodecyl sulfate (SDS) [61]. 
Surviving Leishmania organisms were then quantitated by their conversion of yellow  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into a blue formazan product. 
While Pelargonium extracts, including parent aqueous acetone and methanol extracts as well as 
organic fractions (petroleum ether, ethyl acetate, n-butanol), proved to be inactive against extracellular 
promastigote forms of Leishmania species, pronounced antileishmanial effects were observed against 
intracellular amastigotes that are of clinical and pharmacological importance, with EC50 values ranging 
from < 0.1 to 3.3 µg/mL compared with that of 7.9 µg/mL for Pentostam® as positive control [60]. 
Confirmatory evidence was recently provided by fluorescence activated cell scanning (FACS) analysis 
using transgenic L. major expressing green fluorescent protein (GFP) [62]. This method has significant 
advantages over those involving counting parasites in microscopic preparations and the SDS 
lysis/MTT protocol. Treatment of infected BMMΦ with EPs® 7630 resulted in a significant decrease 
of the intracellular GFP signal in a dose dependent manner and reaffirmed previous results concerning 
the activation of immune defence mechanisms but at single cell levels (Figure 4). That reduction of the 
parasite load was not due to general cytotoxicity followed from addition of propidium iodide before 
FACS measurement in order to discriminate dead (PI-positive cells< 10% in all experiments) from 
living cells. Exposure of infected cells to EPs® 7630 in combination with IFN-γ markedly enhanced 
the effects. For example, the combination of EPs® 7630 (10 µg/mL) plus IFN-γ (100 U/mL) was 
almost as effective as IFN-γ (100 U/mL) plus LPS (10 ng/mL) in killing intracellular parasites [36]. 
Given the crucial role of NO as cytotoxic effector molecule (vide supra), the NO inducing potential 
of Pelargonium extracts and their constituents was determined using the supernatants of sample treated 
macrophage (BMMΦ, RAW 264.7) cultures as a source of secreted NO which was quantitated by 
determining the nitrite concentration using the Griess assay. That the immune response was 
considerably more expressed in infected cells suggests effective stimulation of the non-specific 
immune system when needed. Compared with the positive control (100 U/mL IFN-γ + 10 ng/mL 
LPS), the NO inducing potential of hydrophilic Pelargonium extracts was significantly less prominent. 
However, it should be noted that the induced NO production strongly depended on the kind of 
macrophages (BMMΦ; RAW 264.7) used in experimental models [63]. Inhibition of iNOS by addition 
of L-NMMA produced significantly lower NO levels and concomitantly increased the GFP signal, 




providing strong evidence for the crucial role of NO as toxic effector molecule in the host defence to 
microbial infections and the pronounced NO-inducing capabilities of EPs® 7630. Although a strong 
inverse correlation between NO production and parasite kill was observed, the involvement of 
additional NO-independent defence mechanisms cannot be ruled out. 
Figure 4. Immune response in L. major GFP-infected macrophages treated with EPs® 7630: 
NO production (Griess assay), GFP-positive events (relative survival rates of parasites; FAS 
analysis), and propidium iodide-positive events (dead host cells; FACS analysis). 
 
The above promising results prompted studies with an additional infection model using intracellular 
Listeria monocytogenes bacteria and motivated the pursuit of more relevant studies at the cellular and 
molecular level [64]. This experimental infection model is also commonly used for studying 
antimicrobial defence [65]. Consistent with the Leishmania model, exposure of infected cells to  
EPs® 7630 significantly enhanced NO production in a concentration dependent manner when 
compared to just infected cells. Conspicuously, NO production was already increased at an early time 
point post infection (6 h). Although the survival rate was not measured in this FACS-based assay due 
to non-availability of labelled L. monocytogenes organisms, an efficient elimination of the invading 
pathogens may be anticipated. The data suggest that EPs® 7630 induces NO release in a broad 
spectrum of infectious conditions and, importantly, in therapeutically relevant doses (≤ 30 µg/mL). 
Accordingly, stimulation of the non-specific immune system may be anticipated for intracellular 
residing mycobacteria. Although this still remains to be demonstrated, the present data provide a clue 
for the claimed efficacy of this herbal medicine in the earlier treatment of tuberculosis and related 
diseases in traditional medicine. Interestingly, when tested against macrophages as a mammalian host 
cell control, all samples revealed no or only moderate cytotoxicity. 
2.6.3. Induction of the Release of Tumour Necrosis Factor, IL-1 and IL-12 
Macrophage activation usually is a polyphenotypic event, with TNF release during the early 
response to infection [54]. Measurement of TNF-activity induced by the above mentioned Pelargonium 
extracts was therefore another important immunological parameter in the evaluation of the anti-infective 
potential of this herbal medicine. Initially, TNF-release was assessed in a functional assay [66], in 
which TNF-sensitive ML929F treated with supernatants of sample-activated BMMΦ were rapidly 




lysed in its presence. Surviving cells incorporate crystal violet dye and their relative number was 
spectrophotometrically determined. At the concentration of ≤ 25 µg/mL, the ethyl acetate (ca. 20 U/mL) 
and the n-butanol phase (ca. 19 U/mL) were found to possess a moderate TNF-inducing potential. All 
remaining samples showed only a negligible effect (< 5 U/mL) compared to the LPS stimulus  
(10 ng/mL; 184 U/mL) as positive control [60]. Having in mind that systemic TNF can be fatal the 
moderate TNF-inducing capability of the Pelargonium extracts in non-infected cells may be beneficial. 
This functional bioassay has hitherto not been extended to infected macrophages. However, gene 
expression analysis clearly showed augmented and prolonged up-regulation of TNF-α transcripts in 
infected cells (vide supra). Confirmatory evidence of increased intracellular TNF-α levels induced by 
EPs® 7630 in infectious conditions compared to non-infected cells was recently obtained from FACS 
analysis at single cell levels [64]. Conspicuously, the accumulation of this membrane-bound cytokine 
in stimulated infected cells (ca. 35%) was less pronounced than that in untreated cultures (ca. 45%). 
This phenomenon may be explained by an enhanced activity of the TNF-α converting enzyme 
mediated by the herbal extract. This conjecture found support by increased soluble TNF-α protein 
levels detected by ELISA in the supernatant of infected cells treated with EPs® 7630. The TNF-α titers 
(ca. 10–16 ng/mL; EPs® 7630 test concentrations 1–30 µg/mL) were conspicuously above those of 
both the positive LPS control and infected cells (ca. 10 ng/mL in each case). 
Besides TNF-α, early macrophage-associated cytokine production includes interleukin (IL)-1 and 
IL-12. Analyses of the intracellular/membrane-bound cytokines were again carried out in parallel in 
non-infected and in infected cells in the absence and presence of EPs® 7630, respectively, at single cell 
levels using flow cytometry. ELISA was used for monitoring secreted cytokines in cell supernatants. 
Using BMMΦ experimentally infected with L. monocytogenes, incubation with EPs® 7630 increased 
the production of intra- and extracellular IL-1 and IL-12 when compared to non-infected and just 
infected cells [64]. 
The demonstrated augmented productions of IL-1, IL-12 and TNF-α confirmed once more the 
potential of EPs® 7630 to induce host defence mechanisms for controlling infectious agents at single 
cell level. It is known that IL-1 synergizes with TNF-α in the induction of IL-12 production which, in 
turn, induces IFN-γ release from both NK cells and T cells. IFN-γ in turn mediates protection by 
inducing NO production. Also, the importance of IL-12 in Th1 maturation has been demonstrated, thus 
providing a link between innate and adaptive immunity. 
2.7. Gene Expression Experiments 
Induction of protective immunity against Leishmania infection and other pathogenic agents is 
closely linked to the production of cytokines. The analysis of the data obtained from densitometric 
measurements revealed that the iNOS and cytokine (IL-1, IL-10, IL-12, IL-18, IFN-α, IFN-γ and TNF-α) 
mRNA levels of infected RAW 264.7 cells were significantly enhanced in response to LPS plus IFN-γ 
when compared with those of non-infected cells. Notably, EPs® 7630 produced similar transcript 
profiles with considerably increased and prolonged up-regulations distinctly expressed under infectious 
conditions (Figure 5) [67-69]. 
Transcripts of IL-10, a cytokine associated with downregulatory functions [70], were clearly 
expressed later. This finding independently supported the anti-infective potential of P. sidoides 




observed at functional levels (vide supra). Interestingly, this herbal medicine also stimulated infected 
cells to produce IFN-γ transcripts. The expression of IFN-γ itself in cells of monocytic lineage has 
merely been noted under certain physiological and pathological conditions [71,72]. Also worthy of 
mention is the up-regulation of IL-12 and IL-18 mRNA levels in that both cytokines are critical to host 
defence against a variety of pathogens and are involved in the production of IFN-γ [73,74]. Subsequent 
studies suggested that IFN-γ mRNA expression appeared to be a unique feature of P. sidoides among 
herbal extracts [75]. The gene expression experiments thus provided evidence for macrophage activation 
at the transcriptional level. 
Figure 5. Expression of iNOS and cytokine transcripts in non-infected and in L. major 
infected RAW 264.7 cells stimulated for 4 h with 50 µg/mL of EPs® 7630 and LPS/IFN-γ 
as positive control (ctr). Results are shown relative to hypoxanthine-guanine-phosphoribosyl 
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2.8. Expression of Surface Markers 
Recently, some surface markers became a focus of research interest [64]. CD40 is a member of the 
TNF receptor superfamily, expressed primarily on antigen presenting cells including macrophages. 
This surface marker was found to be an important regulatory receptor for IFN-γ dependent and 
independent host defence mechanisms [76,77] and to be essential for the development of a CD4+ T cell 
mediated immune response [78]. Stimulation of non-infected and Listeria-infected BMMΦ with  
EPs® 7630 moderately enhanced the expression of CD40 [63]. However, it was suggested that this 
herbal medicine may sustain up-regulated CD40 expression in infected conditions as concluded from 
prominent expressions at the very low concentration of 1 µg/mL. 
Stimulation of BMMΦ with LPS + IFN-γ or EPs® 7630 (30 µg/mL) resulted in a dramatic  
down-regulation of the IFN-γ receptor subunit CD119 after 6 h post infection, which may be 
rationalized by internalisation of the receptor. The down-regulation of this receptor under infectious 
conditions was consistent with similar effects in L. monocytogenes infected BMMΦ [79]. Changes in 




the expression of CD119 are suggested to affect the sensitivity of the cell in responding to IFN-γ [80]. 
These limited molecular studies do not allow definite statements, but, at the very least, they do provide 
encouragement for further study of the P. sidoides extract’s mode of action in anti-infective assays. 
2.9. Release of Antimicrobial Peptides 
Polymorphonuclear neutrophils (PMNs) play a key role in the front-line defence against  
pathogens. In addition to recruiting and activating other immune cells, PMNs have been  
demonstrated to release soluble peptides with broad-spectrum antimicrobial activity such as the 
bactericidal/permeability-increasing protein (BPI) and the defensins, human neutrophil peptides (HNP) 
1–3. Recently EPs® 7630 was shown to enhance the release of these antimicrobial peptides in a 
concentration-dependent manner [81]. At 30 µg/mL EPs® 7630 increased the levels of HNP 1–3 and 
BPI by 150% and 127%, respectively. It should be noted that the extract was a much better inducer for 
the release of the defensins than LPS (82%, 10 ng/mL), whereas LPS proved to be more effective for 
BPI (356%). Interestingly, the combination of both stimuli enhanced the release of the studied 
antimicrobial peptides disproportionately (531% and 294% for BPI and HNP 1–3, respectively). This 
finding provided further evidence that the immune system reacts faster and most likely more effective 
against pathogens under the treatment of EPs® 7630 than in the absence of this herbal medicine. 
3. Conclusions 
A traditional South African herbal medicine that has been used for centuries in the empirical 
treatment of respiratory tract diseases has found its way into European laboratories. Recent chemical, 
pharmacological and clinical studies of a special extract, referred to as EPs® 7630 and developed from 
this traditional medicine, proved its efficacy in these conditions. Studying herbs such as P. sidoides for 
effects on the non-specific immune system may lead to the identification of novel chemical structures 
on which newer therapeutic agents can be derived and provide additional insight into the mode of 
action at the molecular level. This example provides a compelling argument for continuing the 
exploration of Nature and traditional medical systems as a source of therapeutically useful herbal 
medicines which satisfy current criteria of quality, safety and efficacy for an evidence-based therapy. 
Acknowledgments 
The unflagging efforts of the co-workers listed on the project’s publications over the past 20 years 
have proven to be an inspiration, and the author is grateful to them all.  
Conflict of Interest 
The author’s work was supported in part by the pharmaceutical company Willmar Schwabe GmbH 
& Co, Karlsruhe, Germany. 
References 
1. WHO. Health statistics and health information systems. Available online: 
http://www.who.int/healthinfo/statistics (accessed on 22 June 2011). 




2. Watt, J.M.; Breyer-Brandwyk, M.G. Medicinal and Poisonous Plants of Southern and Eastern 
Africa; Livingstone: Edinburgh/London, UK, 1962; pp. 449-455. 
3. Hutchings A. Zulu Medicinal Plants; Natal University Press: Pietermaritzburg, South Africa, 
1996. 
4. Kolodziej, H.; Kiderlen, A.F. In vitro evaluation of antibacterial and immunomodulatory activities 
of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation  
EPs® 7630. Phytomedicine 2007, 14, 18-26. 
5. Brendler, T.; van Wyk, B.E. A historical, scientific and commercial perspective on the medicinal 
use of Pelargonium sidoides (Geraniaceae). J. Ethnopharmacol. 2008, 119, 420-433. 
6. Helmstädter, A. Umckaloabo – Late vindication of a secret remedy. Pharm. Historian 1996, 26, 
2-4. 
7. Taylor, P.W.; Maalim, S.; Coleman, S. The strange story of Umckaloabo. Pharmac. J. 2005, 275, 
790-792. 
8. Kolodziej, H. Aqueous ethanolic extract of the roots of Pelargonium sidoides – New scientific 
evidence for an old anti-infective phytopharmaceutica. Planta Med. 2008, 74, 661-666. 
9. Kolodziej, H. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, 
traditional and phytomedicinal sources of the herbal medicine Umckaloabo®. Phytomedicine 
2007, 14, 9-17. 
10. Chuchalin, A.G.; Berman, B.; Lehmacher, W. Treatment of acute bronchitis in adults with a 
Pelargonium sidoides preparation (EPs® 7630): A randomized, double-blind, placebo-controlled 
trial. Explore 2005, 1, 437-445. 
11. Haidvogl, M.; Heger, M. Treatment effect and safety of EPs® 7630-solution in acute bronchitis in 
childhood: Report of a multicentre observational study. Phytomedicine 2007, 14, 60-64. 
12. Matthys, H.; Heger, M. Treatment of acute bronchitis with a liquid herbal drug preparation from 
Pelargonium sidoides (EPs® 7630): A randomised, double-blind, placebo-controlled multicentre 
study. Curr. Med. Res. Opin. 2007, 23, 323-331. 
13. Lizogub, V.G.; Riley, D.S.; Heger, M. Efficacy of a Pelargonium sidoides preparation in patients 
with the common cold: A randomized, double blind, placebo-controlled clinical trial. Explore 
2007, 3, 573-584. 
14. Matthys, H.; Funk, P. EPs® 7630 improves acute bronchitis symptoms and shortens time to 
remission. Results of a randomized, double-blind, placebo-controlled, multicentre trial. Planta 
Med. 2008, 7, 686-692. 
15. Agbabiaka, T.B.; Guo, R.; Ernst, E. Pelargonium sidoides for acute bronchitis: A systematic 
review and meta-analysis. Phytomedicine 2008, 15, 378-385. 
16. Bachert, C.; Schapowal, A.; Funk, P.; Kieser, M. Treatment of acute rhinosinusitis with the 
preparation from Pelargonium sidoides EPs 7630: A randomized, double-blind, placebo-controlled 
trial. Rhinology 2009, 47, 51-55. 
17. Kamin W.; Maydannik, V.G.; Malek, F.A.; Kieser, M. Efficacy and tolerability of EPs 7630 in 
children and adolescents with acute bronchitis: A randomized, double-blind, placebo-controlled 
multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int. J. Clin. 
Pharmacol. Ther. 2010, 48, 184-191. 




18. Kirk, K.M.; Garbes Netto, P.G. Post-marketing surveillance of Pelargonium sidoides for 
treatment of presumably viral acute community acquired tonsillopharyngitis. Rev. Panam. 
Infectol. 2007, 9, 15-24. 
19. Gonzales, R.; Sande, A.M. Uncomplicated acute bronchitis. Ann. Intern. Med. 2000, 133, 981-991. 
20. Gonzales, R.; Bartlett, J.G.; Besser, R.E.; Cooper, R.J.; Hickner, J.M.; Hoffmann, J.R.;  
Sande, A.M. Principles of appropriate antibiotic use for treatment of uncomplicated acute 
bronchitis: Background. Ann. Emerg. Med. 2001, 37, 720-727. 
21. Gödecke, T. Phytochemische und Pharmakologische Untersuchungen an Pelargonium sidoides DC. 
PhD. Thesis, Freie Universität Berlin: Berlin, Germany, 2005. 
22. Taylor, P.W. Antimycobacterial activity of indigenous South African plants. S. Afr. Med. J. 2003, 
93, 904-907. 
23. Seidel, V.; Taylor, P.W. In vitro activity of extracts and constituents of Pelargonium against 
rapidly growing mycobacteria. Int. J. Antimicrob. Agents 2004, 23, 613-619. 
24. Mativandlela, S.N.P.; Lall, N.; Meyer, J.J.M. Antibacterial, antifungal and antitubercular activity 
of Pelargonium reniforme Curtis and Pelargonium sidoides DC. (Geraniaceae) root extracts.  
S. Afr. J. Bot. 2006, 72, 232-237. 
25. Mativandlela, S.N.P.; Meyer, J.J.M.; Hussein, A.A.; Lall, N. Antitubercular activity of 
compounds isolated from Pelargonium sidoides. Pharm. Biol. 2007, 45, 645-650. 
26. Kayser, O.; Kolodziej, H. Antibacterial activity of extracts and constituents of Pelargonium 
sidoides and Pelargonium reniforme. Planta Med. 1997, 63, 508-510. 
27. Uslu, H.; Yoruk, O.; Ayyildiz, A.; Aktan, B. Antibacterial spectrum of Umckaloabo 
(Pelargonium sidoides) on upper airway infection agents. Eur. J. Gen. Med. 2009, 6, 245-248. 
28. Conrad, A.; Jung, I.; Tioua, D.; Lallemand, C.; Carrapatoso, F.; Engels, I.; Daschner, F.D.;  
Frank, U. Extract of Pelargonium sidoides (EPs® 7630) inhibits the interactions of group  
A-streptococci and host epithelia in vivo. Phytomedicine 2007, 14, 52-59. 
29. Janecki, A.; Conrad, A.; Engels, I.; Frank, U.; Kolodziej, H. Evaluation of an aqueous-ethanolic 
extract from Pelargonium sidoides (EPs® 7630) for its activity against group A-streptococci 
adhesion to human HEp-2 cells. J. Ethnopharmacol. 2011, 133, 147-152. 
30. Podbielski, A.; Kreikemeyer, B. The background of tissue specificity of Streptococcus pyogenes. 
Bioforum 2009, 29, 32-34 
31. Beil, W.; Kilian, P. EPs® 7630, an extract from Pelargonium sidoides roots inhibits adherence of 
Helicobacter pylori to gastric epithelial cells. Phytomedicine 2007, 14, 5-8. 
32. Wittschier, N.; Faller, G.; Hensel, A. An extract of Pelargonium sidoides (EPs® 7630) inhibits in 
situ adhesion of Helicobacter pylori to human stomach. Phytomedicine 2007, 14, 285-288. 
33. Neugebauer, P.; Mickenhagen, A.; Siefer, O.; Walger, M. A new approach to pharmacological 
effects on ciliary beat frequency in cell cultures – Exemplary measurements under Pelargonium 
sidoides extract. Phytomedicine 2005, 12, 47-52. 
34. Marcucci, F.; Klein, B.; Kirchner, M.; Zawatzky, R. Production of high titers of interferon gamma 
by prestimulated spleen cells. Eur. J. Immunol. 1982, 12, 787-790. 
35. Kolodziej, H.; Kayser, O.; Radtke, O.A.; Kiderlen, A.F.; Koch, E. Pharmacological profile of 
extracts of Pelargonium sidoides and their constituents. Phytomedicine 2003, 10, 18-24. 




36. Thäle, C.; Kiderlen, A.F.; Kolodziej, H. Anti-infective activities of Pelargonium sidoides  
(EPs® 7630): Effects of induced NO-production on Leismania major in infected macrophages and 
antiviral effects as assessed in a fibroblast-virus protection assay. Planta Med 2011, 77, 718-725. 
37. Schroder, K.; Hertzog, P.J.; Ravani, T.; Hume, D.A. Interferon-γ: An overview of signals, 
mechanisms and functions. J. Leukoc. Biol. 2004, 75, 163-189. 
38. Pestka, S.; Krause, C.D.; Walter, M.R. Interferons, interferon-like cytokines and their receptors. 
Immunol. Rev. 2004, 202, 8-32. 
39. Ank, N.; Iversen, M.B.; Bartholdy, C.; Staeheli, P.; Hartmann, R.; Jensen, U.B.; Dagnaes-Hansen, F.; 
Thomsen, A.R.; Chen, Z.; Haugen, H.; et al. An important role for type III interferon  
(IFN-lamba/IL-2) in TLR-induced antiviral activity. J. Immunol. 2008, 180, 2474-2485. 
40. Koch, E.; Augustin, R.; Wohn, C.; Erdelmeier, C.A.J. Inhibition of mediator release from  
RBL-2H3 cells and human granulocytes by the Pelargonium sidoides root extract EPs® 7630. 
Planta Med. 2010, 76, 1291. 
41. Kolodziej, H.; Kayser, O.; Kiderlen, A.F.; Ito, H.; Hatano, T.; Yoshida, T.; Foo, L.Y. 
Proanthocyanidins and related compounds: Antileishmanial activity and modulatory effects on 
nitric oxide and tumour necrosis factor α release in the murine macrophage-like cell line RAW 
264.7. Biol. Pharm. Bull. 2001, 24, 1016-1021. 
42. Biron, C.A. Interferons α and ß as immune regulators – A new look. Immunity 2001, 41, 661-664. 
43. Schnitzler, P.; Schneider, S.; Stintzing, F.C.; Carle, R.; Reichling, J. Efficacy of an aqueous 
Pelargonium sidoides extract against herpesvirus. Phytomedicine 2008, 15, 1108-1116. 
44. Michaelis, M.; Doerr, H.W.; Cinatl, J., Jr. Investigation of the influence of EPs® 7630, a herbal 
drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory 
viruses. Phytomedicine 2011, 18, 384-386. 
45. von Itzstein, M. The war against influenza: Discovery and development of sialidase inhibitors. 
Nat. Rev. Drug Discov. 2007, 6, 967-974. 
46. Potier, M.; Mameli, L.; Belisle, M.; Dallaire, L.; Melancon, S.B. Fluorometric assay of 
neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate. Anal. 
Biochem. 1979, 94, 287-296. 
47. Janecki, A.J.; Kiderlen, A.F.; Kolodziej, H. In vitro evaluation of EPs® 7630 for its ability to 
inhibit neuraminidase using sodium (4-methyl-umbelliferyl)-α-D-N-acetylneuraminate as substrate. 
Planta Med. 2009, 75, 989. 
48. Muller, C.P. Institute of Immunology, Centre de Recherche Public-Santé/Laboratoire National de 
Santè, Luxembourg. Personal communication, 2011. 
49. Moncada, S.; Palmer, R.M.J.; Higgs, E.A. Nitric oxide: Physiology, pathophysiology, and 
pharmacology. Pharmacol. Rev. 1991, 43, 109-142. 
50. Nathan, C.F.; Hibbs, J. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. 
Opin. Immunol. 1991, 3, 65-70. 
51. Liew, F.Y.; Wei, X.Q.; Proudfoot, L. Cytokines and nitric oxide as effector molecules against 
parasitic infections. Phil. Trans. Royal Soc. Lond. B 1997, 352, 1311-1315. 
52. Bogdan, C.; Röllinghoff, M.; Diefenbach, A. Reactive oxygen and reactive nitrogen intermediates 
in innate and specific immunity. Curr. Opin. Immunol. 2000, 12, 64-76. 




53. Bredt, D.S. Endogeneous nitric oxide synthesis: Biological functions and pathophysiology. Free 
Radic. Res. 1999, 31, 577-596. 
54. Reiner, S.L.; Locksley, R.M. The regulation of immunity to Leishmania major. Annu. Rev. 
Immunol. 1995, 13, 151-177. 
55. Roach, T.I.; Kiderlen, A.F.; Blackwell, J.M. Role of inorganic nitrogen oxides and tumor necrosis 
factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-
activated macrophages from Lshs and Lshr congenic mouse strains. Infect. Immun. 1991, 59, 
3935-3944. 
56. Deng, W.; Thiel, B.; Tannenbau, C.S.; Hamilton, T.A.; Stuehr, D.J. Synergistic cooperation 
between T cell lymphokines for induction of the nitric oxide synthase gene in murine peritoneal 
macrophages. J. Immunol. 1993, 151, 322-329. 
57. Ding, A.H.; Nathan, C.F.; Stuehr, D.J. Release of reactive nitrogen intermediates and reactive 
oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines 
and evidence for independent production. J. Immunol. 1988, 141, 2407-2412. 
58. Ernst, J.D. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 1998, 66,  
1277-1281. 
59. Conrad, A.; Hansmann, C.; Engels, I.; Daschner, F.D.; Frank, U. Extract of Pelargonium sidoides 
(EPs® 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral 
blood phagocytes in vitro. Phytomedicine 2007, 14, 46-51. 
60. Kayser, O.; Kolodziej, H.; Kiderlen, A.F. Immunomodulatory principles of Pelargonium sidoides. 
Phytother. Res. 2001, 15, 122-126. 
61. Kiderlen, A.F.; Kaye, P.M. A modified colorimetric assay of macrophage activation for intracellular 
cytotoxicity against Leishmania parasites. J. Immunol. Methods 1990, 127, 11-18. 
62. Kram, D.; Thäle, C.; Kolodziej, H.; Kiderlen, A.F. Intracellular parasite kill: Flow cytometry and 
NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation. 
J. Immunol. Methods 2008, 333, 79-88. 
63. Kiderlen, A.F.; Kayser, O.; Ferreira, D.; Kolodziej, H. Tannins and related compounds: Killing of 
amastigotes of Leishmania donovani and release of nitric oxide and tumour necrosis factor α in 
macrophages in vitro. Z. Naturforsch. 2001, 56c, 444-454. 
64. Thäle, C.; Kiderlen, A.; Kolodziej, H. Anti-infective mode of action of EPs® 7630 at the 
molecular level. Planta Med. 2008, 74, 675-681. 
65. North, R.J.; Dunn, P.L.; Conlan, J.W. Murine listeriosis as a model for antimicrobial defense. 
Immunol. Rev. 1997, 158, 27-36. 
66. Wagner, H.; Jurcic, K. Methods in Plant Biochemistry; Dey, P.M., Harborne, J.B., Eds.; 
Academic Press: London, UK, 1991; volume 6, pp. 195-217. 
67. Radtke, O.A.; Kiderlen, A.F.; Kayser, O.; Kolodziej, H. Gene expression profiles of inducible 
nitric oxide synthase and cytokines in Leishmania major-infected macrophage-like RAW 264.7 
cells treated with gallic acid. Planta Med. 2004, 70, 924-928. 
68. Kolodziej, H.; Burmeister, A.; Trun, W.; Radtke, O.A.; Kiderlen, A.F.; Ito, H.; Hatano, T.; 
Yoshida, T.; Foo, L.Y. Tannins and related compounds induce nitric oxide synthase and cytokines 
gene expressions in Leishmania major-infected macrophage-like RAW 264.7 cells. Bioorg. Med. 
Chem. 2005, 13, 6470-6476. 




69. Trun, W.; Kiderlen, A.F.; Kolodziej, H. Nitric oxide synthase and cytokines gene expression 
analyses in Leishmania-infected RAW 264.7 cells treated with an extract of Pelargonium sidoides 
(EPs® 7630). Phytomedicine 2006, 13, 570-575. 
70. Mocellin, S.; Panelli, M.C.; Wang, E.; Nagorsen, D.; Marincola, F.M. The dual role of IL-10. 
Trends Immunol. 2003, 24, 36-38 
71. Mogensen, S.C.; Virelizier, J.L. The interferon-macrophage alliance. Interferon 1987, 8, 55-84. 
72. Gessani, S.; Belardelli, F. IFN-γ expression in macrophages and its possible biological significance. 
Cytokine Growth Factor Rev. 1998, 9, 117-123. 
73. Trinchieri, G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that 
bridge innate resistance and antigen specific adaptive immunity. Annu. Rev. Immunol. 1995, 13, 
251-276. 
74. Sugawara, I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases 
induced by intracellular pathogens. Microbes Infect. 2000, 2, 1257-1263. 
75. Kolodziej, H.; Kiderlen, A.F. Antileishmanial activity and immune modulatory effects of tannins 
and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 2005, 66, 
2056-2071. 
76. Andrade, R.M.; Portillo, J.A.; Wessendarp, M.; Subauste, C.S. CD40 signalling in macrophages 
induces activity against an intracellular pathogen independently of gamma interferon and reactive 
nitrogen intermediates. Infect. Immun. 2005, 73, 3115-3123. 
77. Andrade, R.M.; Wessendar, M.; Subauste, C.S. CD154 activates macrophage antimicrobial 
activity in the absence of IFN-gamma through a TNF-alpha-dependent mechanism. J. Immunol. 
2003, 171, 6750-6756. 
78. van Kooten, C.; Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67, 2-17. 
79. Demuth, A.; Goebel, W.; Beuscher, H.U.; Kuhn, M. Differential regulation of cytokine and 
cytokine receptor mRNA expression upon infection of bone marrow-derived macrophages with 
Listeria monocytogenes. Infect. Immun. 1996, 64, 3475-3483. 
80. Tau, G.; Rothman, P. Biologic functions of the IFN-gamma receptors. Allergy 1999, 54,  
1233-1251. 
81. Koch, E.; Wohn, C. Pelargonium sidoides root extract EPs® 7630 stimulates release of  
antimicrobial peptides from neutrophil granulocytes in human whole blood. Planta Med. 2007, 73, 
doi: 10.1055/s-2007-986854. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
